Moderna adds former Biogen CFO Michael McDonnell to board

Moderna, Inc. announced on July 8, 2026 that it had appointed Michael McDonnell to its Board of Directors, effective July 8, 2026¹. According to the company's related 8-K filing, the appointment was made on July 6, 2026, by the Board upon the recommendation of the Nominating and Corporate Governance Committee¹. McDonnell will also serve on the Board's Audit Committee.¹ As part of that change, David Rubenstein ceased to serve as a member of the Audit Committee and was appointed to serve on the Nominating and Corporate Governance Committee¹.

McDonnell brings substantial experience providing financial and accounting leadership to life sciences and technology companies, including more than 24 years serving as chief financial officer of public companies¹. He most recently held the CFO role at Biogen Inc., where he was responsible for a range of finance functions spanning investor relations through business unit finance, a position he held from August 2020 through February 2025, according to the filing. Since leaving Biogen, he has served as an advisor to Goldman Sachs Asset Management¹ starting in March 2025.

Earlier in his career, McDonnell served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc. following the merger of Quintiles and IMS Health¹, and before that held CFO roles at Intelsat S.A., MCG Capital Corporation, and EchoStar Communications Corporation¹. He also spent 14 years at PricewaterhouseCoopers LLP, including four years as a partner¹.

He currently holds board seats at two other companies: he sits on the Merit Medical Systems, Inc. board, chairing its audit committee, and also serves as a director of Baxter International Inc., per the filing.

McDonnell was named a Class II director of the Company, to hold office until the 2029 annual meeting of shareholders or until his earlier death, resignation or removal¹.